Life Science Investing BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S in Women with Hormone Receptor Positive/HER2 Negative Stage II-III Breast Cancer
Life Science Investing BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
Life Science Investing BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process
Life Science Investing BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement
Resource Expansion Drilling Confirms 3,000 metres of New Uranium Trends with Best Drill Hole of 1.4 GT over 7.6 metres
